Pulmonology

Dupilumab is a human monoclonal antibody that mediates improvement in the clinical outcomes of patients diagnosed with moderate-to-severe type 2 asthma, regardless of the status of allergen sensitization. Dupilumab is defined as a human monoclonal antibody that is implicated in different type-2 anti-inflammatory diseases. The previous study demonstrated that dupilumab decreased severe asthma exacerbation and...

This study demonstrates the association between greater odds of asthma attacks in the previous 12 months and higher concentrations of PFDA and PFOA in the serum, which was significant for individuals aged 12 to 18 years. Per- and poly-fluoroalkyl substances (PFAS) are chemicals widely utilized in manufacturing and tend to be highly resistant to degradation;...

This cross-sectional study demonstrated a positive association between the prevalence of asthma and results for the Metabolic Score for Visceral Fat index; however, the relationship is non-linear. There is a negative correlation trend between the prevalence of asthma and the METS-VF index of less than 5.24. The Metabolic Score for Visceral Fat (METS-VF) estimation tool...

Length of stay is one way to measure how severely an illness affects a population. This study analyzes length of stay disparities in several pediatric illnesses, including asthma. Inequities in the quality of care for pediatric illnesses have historically impacted marginalized races and ethnicities in a negative way. Among the many metrics that can be...

Dupilumab is associated with greater improvement in asthma exacerbations than omalizumab and mepolizumab. Multiple monoclonal antibodies (mAbs) are currently approved for asthma treatment. All of these improve outcomes in asthma patients who cannot be controlled with conventional therapy. However, only limited data is available regarding their comparative effectiveness, thus restricting opportunities to optimize patient selection...

Itraconazole as a treatment for severe persistent asthma results in a reduction in bronchial wall thickness and an improvement in symptoms and pulmonary function. Severe persistent asthma (SPA) represents five to ten percent of the total asthma population. Long-term use of inhaled corticosteroids in SPA can result in fungal colonization and inflammation. Various inflammatory mediators...

Asthma treatment varies dramatically worldwide, and this study provides individual-level reporting on medication use and disease severity across various economic categories. Among non-communicable diseases, asthma is one of the most commonly occurring globally, affecting more than 350 million people. Although most asthma patients are able to receive asthma control, this is not attained in many...

Although section 340B of the Public Health Service Act may be effective in other areas, this study shows that it does not seem to limit health disparities among certain populations of patients with asthma. In the United States, patients from many walks of life can have difficulties paying for medical care and medications that are...

Research included a survey showing that people would be likely to use the spray 18 minutes earlier than an injectable medication. Outside advisers for the U.S. Food and Drug Administration voted Thursday to recommend approval of Neffy, the first epinephrine nasal spray for severe allergic reactions. Although most of the Pulmonary-Allergy Drugs Advisory Committee members...